Psoriatic arthritis (PsA) is a form of inflammatory arthritis associated with the skin condition psoriasis. A variety of different treatments are used to try to control arthritis and skin psoriasis and management often involves trial and error to find the right medication for the right person. Very little is known about the decisions made to increase treatment in individual patients. Previous research in rheumatoid arthritis found that clinical measures of disease activity, patient reported outcomes and characteristics of the treating doctor all influenced the decision to change therapy in routine practice. This investigators particularly want to establish whether routine use of the psoriatic arthritis impact of disease (PsAID-12) questionnaire in the clinic setting can enable a better understanding of the impact of PsA on each individual, improve physician-patient communication and lead to appropriate interventions. The PsAID-12 questionnaire is a relatively new European developed questionnaire measuring patient impact across 12 different domains in PsA. This study will use routine implementation of the PsAID-12 questionnaire and see if this is related to treatment decisions and patient satisfaction. The investigators will also examine other factors that may influence treatment decisions including patient characteristics, physician characteristics, disease activity and quality of patient-physician interactions.
This is an observational, cross-sectional study addressing the factors influencing treatment decisions in patients with PsA. Participants will be treated as usual in their routine clinical practice, but decisions on treatment will be recorded - whether treatment is escalated, unchanged or reduced, and why. The study will be conducted in 25 rheumatology centres in Europe (UK, France, Germany, Spain and Italy) with five centres in each country. Each participant will only attend for one single study visit which is likely to last around 30 minutes in total. This will be alongside the participant's routine clinic visit. The PsAID-12 questionnaire will be implemented on a tablet computer but the remaining outcomes will be collected on paper CRFs and transferred to a database for analysis.
Study Type
OBSERVATIONAL
Enrollment
503
PsAID questionnaire
CHU Gabriel-Montpied
Clermont-Ferrand, France
Centre Hospitalier Le Mans
Le Mans, France
Hopitaux Universitaires de Marseille
Marseille, France
GERPAL, Hopital de la Pitie
Paris, France
Centre Hospitalier Universitaire (CHU) de Toulouse
Toulouse, France
Klinikum Bamburg
Bamberg, Germany
Rheumatologische Schwerpunktpraxis
Berlin, Germany
Universitatsklinik Frankfurt
Frankfurt, Germany
Universitätsklinikum der Ruhr-Universität Bochum
Herne, Germany
MVZ für Rheumatologie Dr. Martin Welcker GmbH
Planegg, Germany
...and 11 more locations
Number of Patients Undergoing Treatment Escalation
Treatment escalation definition includes increase in dose, frequency, change of route, new medication
Time frame: During the consultation visit (around 30-60 mins)
Number of Patients Undergoing Reduction of Therapy
Treatment reduction definition includes decrease in dose, frequency, change in route, stopping medication
Time frame: During the consultation visit (around 30-60 mins)
Mean PsAID-12 Scores
PsA impact of disease score (scale 0-10 where higher score is worse)
Time frame: During the consultation visit (around 30-60 mins)
Median CollaboRATE Score
Patient satisfaction with consultation (scale 0-9 where higher score is better)
Time frame: During the consultation visit (around 30-60 mins)
Median Perceived Efficacy on Patient-physician Interaction Score (PEPPI)
A patient-reported questionnaire to assess their perceived efficacy in a healthcare consultation. This consists of 5 questions which the patient rates on a likert scale of 1 to 5. The score for each of the questions are summed together giving a score range of 5-25 where higher score is better)
Time frame: During the consultation visit (around 30-60 mins)
Median Score for Physicians Opinion of How PsAID 12 Influenced Treatment Decision
Likert scale 1-5 where 1. A lot more likely to decrease or not change therapy 2. Somewhat more likely to decrease or not change therapy 3. No impact on treatment decision 4. Somewhat more likely to increase therapy 5. A lot more likely to increase therapy A higher score means that the PsAID 12 was more likely to influence treatment decisions.
Time frame: During the consultation visit (around 30-60 mins)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.